Drug Shortage Report for DOXORUBICIN HYDROCHLORIDE INJECTION

Last updated on 2020-06-25 History
Report ID 118253
Drug Identification Number 02409275
Brand name DOXORUBICIN HYDROCHLORIDE INJECTION
Common or Proper name DOXORUBICIN INJ 200MG/100ML
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) DOXORUBICIN HYDROCHLORIDE
Strength(s) 2MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVESICAL INTRAVENOUS INTRAVESICAL
Packaging size 1
ATC code L01DB
ATC description CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-06-17
Estimated end date 2020-07-31
Actual end date 2020-06-24
Shortage status Resolved
Updated date 2020-06-25
Company comments
Health Canada comments
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v4 2020-06-25 French Compare
v3 2020-06-25 English Compare
v2 2020-06-18 French Compare
v1 2020-06-18 English Compare